Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019001079
Abstract: CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates… read more here.
Keywords: cd27; hematologic malignancies; novel first; varlilumab novel ... See more keywords